MCID: SKN005
MIFTS: 40

Skin Atrophy malady

Categories: Skin diseases

Aliases & Classifications for Skin Atrophy

Aliases & Descriptions for Skin Atrophy:

Name: Skin Atrophy 12 14
Atrophic Condition of Skin 12 69
Atrophy - Skin 12
Atrophoderma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2733
ICD10 33 L90 L90.9
NCIt 47 C35163
UMLS 69 C0151514

Summaries for Skin Atrophy

MalaCards based summary : Skin Atrophy, also known as atrophic condition of skin, is related to atrophoderma of pierini and pasini and atrophoderma vermiculata. An important gene associated with Skin Atrophy is FERMT1 (Fermitin Family Member 1), and among its related pathways/superpathways are Cytoskeletal Signaling and Adhesion. The drugs Tacrolimus and Pimecrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and testes, and related phenotypes are growth/size/body region and cellular

Wikipedia : 71 Atrophoderma refers to conditions involving skin... more...

Related Diseases for Skin Atrophy

Graphical network of the top 20 diseases related to Skin Atrophy:



Diseases related to Skin Atrophy

Symptoms & Phenotypes for Skin Atrophy

MGI Mouse Phenotypes related to Skin Atrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.03 CD44 EBP FERMT1 GJA1 HBEGF KL
2 cellular MP:0005384 10.02 CD44 FBLIM1 FERMT1 GJA1 KL LMNA
3 immune system MP:0005387 9.95 CD44 FBLIM1 FERMT1 GJA1 KL LMNA
4 mortality/aging MP:0010768 9.92 CD44 EBP FERMT1 GJA1 HBEGF KL
5 integument MP:0010771 9.91 LMNA CD44 EBP FERMT1 GJA1 HBEGF
6 digestive/alimentary MP:0005381 9.85 CD44 FERMT1 KL LMNA TCOF1
7 muscle MP:0005369 9.65 CD44 GJA1 HBEGF KL LMNA
8 respiratory system MP:0005388 9.63 CD44 GJA1 HBEGF KL LMNA TCOF1
9 skeleton MP:0005390 9.5 CD44 FBLIM1 GJA1 HBEGF KL LMNA
10 vision/eye MP:0005391 9.02 CD44 GJA1 KL LMNA TCOF1

Drugs & Therapeutics for Skin Atrophy

Drugs for Skin Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
2
Pimecrolimus Approved, Investigational Phase 4,Phase 2 137071-32-0 6447131 17753757
3
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
4
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
5
Hydroquinone Approved Phase 4,Phase 2 123-31-9 785
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Goserelin Approved Phase 4 65807-02-5 47725 5311128
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
10
Methylprednisolone Approved, Vet_approved Phase 4,Early Phase 1 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 4,Early Phase 1 50-24-8 5755
12
Adapalene Approved Phase 4 106685-40-9 60164
13
Benzoyl peroxide Approved Phase 4 94-36-0 7187
14
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
15
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
16 Anti-Allergic Agents Phase 4,Phase 1
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Calcineurin Inhibitors Phase 4,Phase 2
19 Dermatologic Agents Phase 4,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
21 mometasone furoate Phase 4,Phase 1 83919-23-7
22 Analgesics Phase 4,Phase 2
23 Analgesics, Non-Narcotic Phase 4,Phase 2
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
25 Antirheumatic Agents Phase 4,Phase 2
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Early Phase 1
27 Antioxidants Phase 4,Phase 2,Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Keratolytic Agents Phase 4,Phase 2
33 Protective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
34 triamcinolone acetonide Phase 4,Phase 2
35 Triamcinolone diacetate Phase 4,Phase 2
36 Triamcinolone hexacetonide Phase 4,Phase 2
37 Radiation-Protective Agents Phase 4
38 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 1
39 Autonomic Agents Phase 4,Early Phase 1
40 Bronchodilator Agents Phase 4
41 Epinephryl borate Phase 4
42
Fluticasone Phase 4 90566-53-3, 80474-14-2 62924 22833648
43 Racepinephrine Phase 4
44 Respiratory System Agents Phase 4,Phase 2,Phase 1
45
Clobetasol Phase 4,Phase 3,Phase 2,Phase 1 25122-46-7 32798 5311051
46 EMLA Phase 4
47 Emollients Phase 4,Phase 1,Phase 2
48 Anti-Infective Agents Phase 4,Phase 1,Phase 2
49 Antiparasitic Agents Phase 4
50 Antiprotozoal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 137)
id Name Status NCT ID Phase
1 Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo Unknown status NCT01333410 Phase 4
2 Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis Completed NCT00367393 Phase 4
3 Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma Completed NCT00469183 Phase 4
4 Cutivate Lotion HPA Axis Pediatric Study Completed NCT00546000 Phase 4
5 Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails Completed NCT01703325 Phase 4
6 Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
7 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients Completed NCT00121316 Phase 4
8 Evaluation of Eflornithine on Facial and Forearm Skin Completed NCT00152048 Phase 4
9 A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric S Completed NCT01915914 Phase 4
10 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4
11 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4
12 Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis Completed NCT01111123 Phase 4
13 Efficacy Study of Local Steroid Injection and Wrist Splinting for Carpal Tunnel Syndrome Completed NCT02140632 Phase 4
14 Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis Completed NCT00185510 Phase 4
15 Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars Active, not recruiting NCT02735421 Phase 4
16 Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids Unknown status NCT00709579 Phase 3
17 Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis Completed NCT00658788 Phase 3
18 S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults Completed NCT00110747 Phase 3
19 Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty Completed NCT01096524 Phase 3
20 Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients Completed NCT00607295 Phase 3
21 S9626: Megestrol in Treating Hot Flashes Following Treatment for Breast Cancer Completed NCT00005975 Phase 3
22 Reproductive Health Survivorship Care Plan Recruiting NCT02667626 Phase 3
23 Modafinil to Treat Fatigue in Post-Polio Syndrome Terminated NCT00067496 Phase 3
24 Efficacy of TCA Effect on Varicella Atrophic Scars Unknown status NCT00422539 Phase 2
25 Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo Unknown status NCT01766609 Phase 2
26 The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars Unknown status NCT02126657 Phase 2
27 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
28 A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus Unknown status NCT01524744 Phase 2
29 Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test Completed NCT02111499 Phase 1, Phase 2
30 Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment Completed NCT01553773 Phase 2
31 Interest of Topical Spironolactone's Administration to Prevent Corticoid-induced Epidermal Atrophy Completed NCT01407471 Phase 2
32 Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA) Completed NCT00303446 Phase 2
33 Effect of Electrical Muscle Stimulation in Critically Ill Patients Completed NCT01637467 Phase 1, Phase 2
34 Fractional Resurfacing Device for Treatment of Acne Scarring Completed NCT00585286 Phase 1, Phase 2
35 The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Completed NCT02106468 Phase 2
36 Cedar Honey in Oral Lichen Planus Completed NCT01974414 Phase 1, Phase 2
37 Effect of Potassium Bicarbonate Supplementation on Bone and Muscle in Older Adults Completed NCT00357214 Phase 2
38 Biological Effects of Weight Loss In Older, Obese Women Completed NCT01032733 Phase 2
39 Adipose Derived Stem Cells in Facial Fat Grafting Recruiting NCT02526576 Phase 2
40 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Recruiting NCT01086540 Phase 2
41 Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Recruiting NCT03033108 Phase 2
42 Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus Recruiting NCT03026478 Phase 2
43 A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Recruiting NCT02760264 Phase 2
44 An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) Recruiting NCT02760277 Phase 2
45 Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) Active, not recruiting NCT00950248 Phase 1, Phase 2
46 Novel Compositions for Treating or Preventing Dermal Disorders Not yet recruiting NCT03103893 Phase 1, Phase 2
47 Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study Not yet recruiting NCT02810015 Phase 2
48 Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Suspended NCT01122342 Phase 1, Phase 2
49 Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Unknown status NCT02034786 Phase 1
50 Therapeutic Effect of Quercetin and the Current Treatment of Erosive and Atrophic Oral Lichen Planus Unknown status NCT01375101 Phase 1

Search NIH Clinical Center for Skin Atrophy

Genetic Tests for Skin Atrophy

Anatomical Context for Skin Atrophy

MalaCards organs/tissues related to Skin Atrophy:

39
Skin, Thyroid, Testes, Tongue

Publications for Skin Atrophy

Articles related to Skin Atrophy:

(show all 48)
id Title Authors Year
1
Surgical Answer to Intralesional Steroid-Induced Skin Atrophy. ( 27870650 )
2016
2
Acral skin atrophy in an infant: an early clue to Kindler syndrome diagnosis. ( 25764106 )
2015
3
Topical corticosteroid-induced skin atrophy: a comprehensive review. ( 25862024 )
2015
4
Resveratrol Derivative-Rich Melinjo Seed Extract Attenuates Skin Atrophy in Sod1-Deficient Mice. ( 26180586 )
2015
5
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 24488534 )
2014
6
Collagen peptide and vitamin C additively attenuate age-related skin atrophy in Sod1-deficient mice. ( 25229861 )
2014
7
Palladium and Platinum Nanoparticles Attenuate Aging-Like Skin Atrophy via Antioxidant Activity in Mice. ( 25333617 )
2014
8
Hyalurosome gene regulation and dose-dependent restoration of skin atrophy by retinaldehyde and defined-size hyaluronate fragments in dermatoporosis. ( 25138066 )
2014
9
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. ( 25027750 )
2014
10
Validation of Dermaphot(Ar) for the assessment of steroid-induced skin atrophy. ( 23242470 )
2013
11
Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy. ( 22249456 )
2012
12
Linear skin atrophy preceding calcinosis cutis in pseudo-pseudohypoparathyroidism. ( 22299648 )
2012
13
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy. ( 22512680 )
2012
14
Vulvar skin atrophy induced by topical glucocorticoids. ( 22594868 )
2012
15
Shortened treatment duration of glucocorticoid-induced skin atrophy in rats. ( 21824195 )
2011
16
Evaluation of skin atrophy associated with linear atrophoderma of Moulin by ultrasound imaging. ( 21679833 )
2011
17
Test systems for the determination of glucocorticoid receptor ligand induced skin atrophy. ( 22110776 )
2011
18
Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy. ( 20051715 )
2010
19
A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. ( 19755910 )
2009
20
Skin atrophy in cytoplasmic SOD-deficient mice and its complete recovery using a vitamin C derivative. ( 19289104 )
2009
21
In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. ( 18246695 )
2008
22
Loss of Kindlin-1 causes skin atrophy and lethal neonatal intestinal epithelial dysfunction. ( 19057668 )
2008
23
Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans. ( 17123343 )
2006
24
Hyaluronate fragments reverse skin atrophy by a CD44-dependent mechanism. ( 17177600 )
2006
25
Skin atrophy caused by thiocolchicoside injections. ( 17184273 )
2006
26
Action of topical thyroid hormone analogues on glucocorticoid-induced skin atrophy in mice. ( 16571090 )
2006
27
Glucocorticoid therapy-induced skin atrophy. ( 16689857 )
2006
28
Dose-response effects of tri-iodothyroacetic acid (Triac) and other thyroid hormone analogues on glucocorticoid-induced skin atrophy in the haired mouse. ( 12353707 )
2002
29
Topical tacrolimus and pimecrolimus are not associated with skin atrophy. ( 11903264 )
2002
30
The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. ( 11260007 )
2001
31
Eyelid skin atrophy associated with chronic usage of ophthalmic steroid ointment, and its successful treatment with the Versapulse laser. ( 11702982 )
2001
32
Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. ( 9553910 )
1998
33
The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. ( 9990383 )
1998
34
Skin atrophy of the eyelid induced by topical ophthalmic corticosteroids. ( 9686858 )
1998
35
Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application. ( 7894098 )
1995
36
In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin. ( 8106754 )
1994
37
Morphometric computerized analysis as a method to assess skin atrophy caused by corticosteroids. ( 8489771 )
1993
38
Combination of a dual 5-lipoxygenase/cyclooxygenase inhibitor with a glucocorticoid results in synergistic topical antiinflammatory activity without inducing skin atrophy. ( 8225561 )
1993
39
0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. ( 1618247 )
1992
40
Topical all-trans-retinoic acid prevents corticosteroid-induced skin atrophy without abrogating the anti-inflammatory effect. ( 2768567 )
1989
41
Remote skin atrophy caused by topical steroids. ( 21253139 )
1988
42
Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo. ( 3888708 )
1985
43
Linear skin atrophy, scarring alopecia, anonychia, and tongue lesion: a "new" syndrome? ( 4040704 )
1985
44
Infection and prematurity as the cause of linear skin atrophy, alopecia, anonychia, and tongue lesions? ( 3901928 )
1985
45
A study of potential skin atrophy following topical application of weak corticosteroids. ( 7261664 )
1981
46
Comparative evaluation of skin atrophy in man induced by topical corticoids. ( 154921 )
1979
47
Periarticular perilymphatic skin atrophy after intra-articular corticosteroid injections. ( 671670 )
1978
48
Mechanism of local skin atrophy caused by intradermally injected corticosteroids. ( 133836 )
1976

Variations for Skin Atrophy

Expression for Skin Atrophy

Search GEO for disease gene expression data for Skin Atrophy.

Pathways for Skin Atrophy

GO Terms for Skin Atrophy

Cellular components related to Skin Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.35 CD44 EBP GJA1 HBEGF KL
2 focal adhesion GO:0005925 8.92 CD44 FBLIM1 FERMT1 GJA1

Molecular functions related to Skin Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.62 HBEGF KL

Sources for Skin Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....